While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal’s Zegfrovy (sunvozertinib) to treat a ...

Early commercialisation is one of the most demanding stages in bringing a therapy to market, and the challenges are only ...

A WHO report emphasises the serious global impact of antimicrobial resistance, which exacerbates the substantial burden of ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

UCB has shared promising results from a late-stage study of fenfluramine in patients with an ultra-rare form of epilepsy. The ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).